EGFR inhibitors such as monoclonal antibodies or small molecule TKIs have been approved for the therapy of non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal cancers [52–54]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.